# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Calumet, Inc. (NASDAQ:CLMT) ("Calumet, ""we," "our" or "us") provided an update regarding the r...
UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $12 to $13.25.
Calumet, Inc. (NASDAQ:CLMT) ("Calumet" or the "Company") announced today that it has extended its Shreveport te...
Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:CLMT) with a Overweight and lowers the price target from $23 to $21.
Calumet shares rise after analyst highlights MaxSAF-driven EBITDA growth and debt reduction potential.
B of A Securities analyst Conor Fitzpatrick initiates coverage on Calumet (NASDAQ:CLMT) with a Buy rating and announces Pric...